Deals

Chai Discovery Announces Collaboration with GSK – AI Protein Folding and Design Platform to Power Drug Discovery Across GSK's Pipeline
AIChai Discovery

Chai Discovery Announces Collaboration with GSK – AI Protein Folding and Design Platform to Power Drug Discovery Across GSK’s Pipeline

Chai Discovery, the AI company building a computer-aided design suite for molecules, announced a collaboration with biopharma company GlaxoSmithKline Plc (GSK; NYSE: GSK) following a successful technology evaluation. Under the…

Sun‑Novo and Vanguard Pharmaceutical Sign Co‑Development Agreement for ABA001 – GalNAc‑Conjugated siRNA Targeting Angiotensinogen in Hypertension

Sun‑Novo and Vanguard Pharmaceutical Sign Co‑Development Agreement for ABA001 – GalNAc‑Conjugated siRNA Targeting Angiotensinogen in Hypertension

Chengda Biotechnology Acquires Recombinant Quadrivalent Enterovirus Vaccine Technology for RMB 46 Million – Strengthening Its HFMD Vaccine Pipeline Beyond EV71

Chengda Biotechnology Acquires Recombinant Quadrivalent Enterovirus Vaccine Technology for RMB 46 Million – Strengthening Its HFMD Vaccine Pipeline Beyond EV71

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Suzhou Zelgen Biopharma to Deregister U.S. Subsidiary Gensun to Sharpen R&D Focus
Gensun BiopharmaSHA: 688266

Suzhou Zelgen Biopharma to Deregister U.S. Subsidiary Gensun to Sharpen R&D Focus

MSD Acquires Cidara Therapeutics in $9.2‑Billion Deal to Expand Antiviral Portfolio
Cidara TherapeuticsMerck Sharp & Dohme

MSD Acquires Cidara Therapeutics in $9.2‑Billion Deal to Expand Antiviral Portfolio

BrightGene Boosts Stake in Geek Gene to 12.8% with RMB 50 M Injection – Expanding Cell‑Therapy Portfolio
BiotechBrightGene Bio-Medical Technology

BrightGene Boosts Stake in Geek Gene to 12.8% with RMB 50 M Injection – Expanding Cell‑Therapy Portfolio

Adagene Licenses SAFEbody Platform to Third Arc Bio for Masked CD3 T‑Cell Engagers
AdageneNASDAQ: ADAG

Adagene Licenses SAFEbody Platform to Third Arc Bio for Masked CD3 T‑Cell Engagers

Show More